DJ-927 and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed solid tumor
• * Locally advanced or metastatic disease
• Minimally pretreated
• No symptomatic brain metastases
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• ECOG 0-2
• Life expectancy
• At least 3 months
• Hematopoietic
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Hepatic
• SGOT and SGPT no greater than 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases are present)
• Bilirubin no greater than 1.5 times ULN
• Renal
• Creatinine no greater than 1.5 times ULN
• Gastrointestinal
• No prior chronic diarrhea
• No swallowing and/or malabsorption problems
• No diarrhea (excess of 2-3 stools/day above normal frequency in the past month)
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• HIV negative
• No prior severe or life-threatening hypersensitivity reaction to a taxane or capecitabine
• No concurrent serious infection
• No neuropathy grade 2 or greater
• No other malignancy within the past 2 years except nonmelanoma skin cancer or carcinoma in situ of the cervix
• No other severe or uncontrolled underlying medical disease that would preclude study participation
• No psychiatric disorder that would preclude giving informed consent or study compliance
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• No concurrent anticancer biologic therapy
• Chemotherapy
• Recovered from prior chemotherapy
• No other concurrent anticancer chemotherapy
• Endocrine therapy
• Not specified
• Radiotherapy
• Recovered from prior radiotherapy
• No concurrent anticancer radiotherapy
• * Concurrent localized radiotherapy to a non-indicator lesion for pain relief is allowed provided other methods of pain control are ineffective
• Surgery
• At least 4 weeks since prior major surgery and recovered
• No prior major surgery in the stomach or small intestine
• Other
• At least 4 weeks since prior myelosuppressive therapy
• More than 28 days since prior investigational drugs (including analgesics and/or antiemetics)
• No other concurrent anticancer therapy
• No other concurrent anticancer cytotoxic therapy